Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies
Antoni Ribas, Madhav V. Dhodapkar, Katie M. Campbell, et al.
Blood Cancer Discovery (2021) Vol. 2, Iss. 6, pp. 562-567
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
Annika Fendler, Elisabeth G.E. de Vries, Corine H. GeurtsvanKessel, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 6, pp. 385-401
Open Access | Times Cited: 178
CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity
Tanaya Shree, Vishnu Shankar, Julian J.K. Lohmeyer, et al.
Blood Cancer Discovery (2022) Vol. 3, Iss. 2, pp. 95-102
Open Access | Times Cited: 41
Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Andrés Chang, Akil Akhtar, Susanne L. Linderman, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 26, pp. 3020-3031
Open Access | Times Cited: 40
COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches
Sareh Kakavandi, Bahareh Hajikhani, Paniz Azizi, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 7
Seroconversion and outcomes after initial and booster COVID‐19 vaccination in adults with hematologic malignancies
Thomas Ollila, Rebecca Masel, John L. Reagan, et al.
Cancer (2022) Vol. 128, Iss. 18, pp. 3319-3329
Open Access | Times Cited: 34
mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patients
Elena Azzolini, Chiara Pozzi, Luca Germagnoli, et al.
Life Science Alliance (2022) Vol. 5, Iss. 6, pp. e202201381-e202201381
Open Access | Times Cited: 33
The immune system in multiple myeloma and precursor states: Lessons and implications for immunotherapy and interception
Madhav V. Dhodapkar
American Journal of Hematology (2022) Vol. 98, Iss. S2
Open Access | Times Cited: 28
Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19
Juan G. Ripoll, Sidna M. Tulledge‐Scheitel, Anthony A. Stephenson, et al.
mBio (2024) Vol. 15, Iss. 5
Open Access | Times Cited: 6
Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections
Maryam I. Azeem, Ajay K. Nooka, Uma Shanmugasundaram, et al.
Blood Cancer Discovery (2022) Vol. 4, Iss. 2, pp. 106-117
Open Access | Times Cited: 26
Vaccine-boosted convalescent plasma therapy for patients with immunosuppression and COVID-19
Juan G. Ripoll, Ellen K. Gorman, Justin E. Juskewitch, et al.
Blood Advances (2022) Vol. 6, Iss. 23, pp. 5951-5955
Open Access | Times Cited: 24
Anti-spike T-cell and Antibody Responses to SARS-CoV-2 mRNA Vaccines in Patients with Hematologic Malignancies
Lee M. Greenberger, Larry A. Saltzman, Lore Gruenbaum, et al.
Blood Cancer Discovery (2022) Vol. 3, Iss. 6, pp. 481-489
Open Access | Times Cited: 21
Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients
Spyridoula Vasileiou, LaQuisa C. Hill, Manik Kuvalekar, et al.
Haematologica (2022) Vol. 108, Iss. 7, pp. 1840-1850
Open Access | Times Cited: 20
Vaccination for SARS-CoV-2 in Hematological Patients
Niccolò Riccardi, Marco Falcone, Dafna Yahav
Acta Haematologica (2022) Vol. 145, Iss. 3, pp. 257-266
Open Access | Times Cited: 14
Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies
Cristina Bergamaschi, Maria Pagoni, Margherita Rosati, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 12
Spike and nucleocapsid antibody dynamics following SARS‐CoV‐2 infection and vaccination: Implications for sourcing COVID‐19 convalescent plasma from routinely collected blood donations
Clara Di Germanio, Xutao Deng, Brendan G. Balasko, et al.
Transfusion (2024) Vol. 64, Iss. 11, pp. 2063-2074
Open Access | Times Cited: 1
Covid-19 in patients with haematological malignancies
Hubert Warda, Katarzyna Skórka, Krzysztof Giannopoulos
Acta Haematologica Polonica (2024) Vol. 55, Iss. 2, pp. 73-89
Open Access | Times Cited: 1
Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies
Jane C. Figueiredo, Fred R. Hirsch, Lawrence H. Kushi, et al.
Open Forum Infectious Diseases (2022) Vol. 9, Iss. 6
Open Access | Times Cited: 7
mRNA COVID-19 vaccine booster fosters B and T cell responses in immunocompromised patients
Elena Azzolini, Chiara Pozzi, Luca Germagnoli, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 5
Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies
Andrés Chang, Akil Akhtar, Lilin Lai, et al.
Cancer Research Communications (2022) Vol. 2, Iss. 12, pp. 1684-1692
Open Access | Times Cited: 5
Gatekeepers in research: the experience of recruiting carers of people with chronic blood cancers
Orlaith Cormican, Maura Dowling
Nurse Researcher (2023) Vol. 31, Iss. 3, pp. 15-21
Closed Access | Times Cited: 2
Humoral response to mRNA-based COVID-19 vaccine and booster effect of a third dose in patients with mature T cell and NK-cell neoplasms
Mirei Kobayashi, Akio Mori, Masahiro Onozawa, et al.
Annals of Hematology (2023) Vol. 102, Iss. 4, pp. 819-827
Open Access | Times Cited: 2
Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Replacement Therapy for Immunocompromised Patients
Jonathon W. Senefeld, Michael J. Joyner
Clinical Infectious Diseases (2023) Vol. 77, Iss. 7, pp. 961-963
Closed Access | Times Cited: 2
Clinical characteristics of COVID-19 and the efficacy of vaccination in patients with hematologic malignancies
Olivera Marković, Anica Divac, Ilija Bukurecki, et al.
Srpski medicinski casopis Lekarske komore (2022) Vol. 3, Iss. 1, pp. 75-86
Open Access | Times Cited: 1
Data from Impaired SARS-CoV-2 Variant Neutralization and CD8<sup>+</sup> T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections
Maryam I. Azeem, Ajay K. Nooka, Uma Shanmugasundaram, et al.
(2023)
Open Access
Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19
Juan G. Ripoll, Sidna M. Tulledge‐Scheitel, Anthony A. Stephenson, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Page 1 - Next Page

Scroll to top